OCTA and Polypoidal Choroidal Vasculopathy

Choroid and Choriocapillary Changes in Polypoidal Choroidal Vasculopathy After Intravitreal Anti-VEGF Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04714242

Enrollment

Registered

2021-01-19

Start date

2019-01-15

Completion date

2020-12-20

Last updated

2021-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal Choroidal Vasculopathy

Brief summary

To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

Detailed description

Polypoidal choroidal vasculopathy represents a distinct form of choroidal neovascularization. The study investigated the changes in choroidal vascular network after anti-VEGF therapy using optical coherence tomography angiography, a novel and non invasive diagnostic technique that allows to better understand the pathophysiologic mechanism of this neovascularization.

Interventions

DRUGRanibizumab Injection

Three monthly intravitreal injections of Ranibizumab

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to 80 Years

Inclusion criteria

* age older than 60 years * diagnosis of polypoidal choroidal vasculopathy * absence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. * absence of significant lens opacities, low-quality OCT-A images.

Exclusion criteria

* age older than 80 years * absence of diagnosis of polypoidal choroidal vasculopathy * presence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. * presence of significant lens opacities, low-quality OCT-A images.

Design outcomes

Primary

Measure	Time frame	Description
Study of vascular features of choroid in polypoidal choroidal vasculopathy after intravitreal injections of Ranibizumab	12 Months	The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: choriocapillaris vessel density.

Secondary

Measure	Time frame	Description
Study of structural features of choroid in polypoidal choroidal vasculopathy after intravitreal	12 Months	The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography. The parameters analyzed by optical coherence tomography were: subfoveal choroidal thickness.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026